InvestorsHub Logo
Followers 33
Posts 2843
Boards Moderated 2
Alias Born 10/24/2015

Re: flipper44 post# 156525

Thursday, 02/01/2018 9:53:41 AM

Thursday, February 01, 2018 9:53:41 AM

Post# of 704700
CpG can target either plasmacytoid dendritic cells and/or B-cells (depending on the class). The former (immature) are recruited to a tumour and then are converted to help maintain tolerance/suppression http://onlinelibrary.wiley.com/doi/10.1189/jlb.0812397/full

Intratumoral injections of one drug (FLT3L) http://www.cell.com/cancer-cell/fulltext/S1535-6108(14)00370-5 http://www.cell.com/immunity/fulltext/S1074-7613(16)30101-7 could help increase certain DC subsets and then these could be targeted with different TLR agonists https://jitc.biomedcentral.com/articles/10.1186/2051-1426-2-12

Or you could combine CpG with a range of mAb's and inject them all into the tumour https://www.jci.org/articles/view/64859
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News